These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 27389078)

  • 21. Diabetic nephropathy as a cause of end-stage renal disease in Egypt: a six-year study.
    Afifi A; El Setouhy M; El Sharkawy M; Ali M; Ahmed H; El-Menshawy O; Masoud W
    East Mediterr Health J; 2004; 10(4-5):620-6. PubMed ID: 16335654
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of (pro)renin receptor in human kidneys with end-stage kidney disease due to diabetic nephropathy.
    Takahashi K; Yamamoto H; Hirose T; Hiraishi K; Shoji I; Shibasaki A; Kato I; Kaneko K; Sasano H; Satoh F; Totsune K
    Peptides; 2010 Jul; 31(7):1405-8. PubMed ID: 20385187
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pathophysiology of diabetic nephropathy: involvement of multifaceted signalling mechanism.
    Balakumar P; Arora MK; Reddy J; Anand-Srivastava MB
    J Cardiovasc Pharmacol; 2009 Aug; 54(2):129-38. PubMed ID: 19528810
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Allograft diabetic nephropathy may progress to end-stage renal disease.
    Salifu MO; Nicastri AD; Markell MS; Ghali H; Sommer BG; Friedman EA
    Pediatr Transplant; 2004 Aug; 8(4):351-6. PubMed ID: 15265161
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Advances in the treatment of diabetic renal disease: focus on losartan.
    Rayner B
    Curr Med Res Opin; 2004 Mar; 20(3):333-40. PubMed ID: 15025842
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BP and Renal Outcomes in Diabetic Kidney Disease: The Veterans Affairs Nephropathy in Diabetes Trial.
    Leehey DJ; Zhang JH; Emanuele NV; Whaley-Connell A; Palevsky PM; Reilly RF; Guarino P; Fried LF;
    Clin J Am Soc Nephrol; 2015 Dec; 10(12):2159-69. PubMed ID: 26482258
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Renal complications of diabetes.
    Min TZ; Stephens MW; Kumar P; Chudleigh RA
    Br Med Bull; 2012; 104():113-27. PubMed ID: 23118262
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preventing end stage renal disease in diabetic patients--genetic aspect (part I).
    Jacobsen PK
    J Renin Angiotensin Aldosterone Syst; 2005 Mar; 6(1):1-14. PubMed ID: 16088846
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Health economic consequences of the use of irbesartan in patients in Germany with type 2 diabetes, nephropathy and hypertension].
    Palmer AJ; Annemans L; Roze S; Lamotte M; Rodby RA; Ritz E
    Dtsch Med Wochenschr; 2004 Jan; 129(1-2):13-8. PubMed ID: 14703575
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Renal complications of diabetes].
    Tielemans C
    Rev Med Brux; 1995; 16(4):258-61. PubMed ID: 7481238
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Individualized prediction of the effect of angiotensin receptor blockade on renal and cardiovascular outcomes in patients with diabetic nephropathy.
    van der Sande NG; Dorresteijn JA; Visseren FL; Dwyer JP; Blankestijn PJ; van der Graaf Y; Heerspink HL
    Diabetes Obes Metab; 2016 Nov; 18(11):1120-1127. PubMed ID: 27337598
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [DIABETIC NEPHROPATHY AS A CAUSE OF CHRONIC KIDNEY DISEASE].
    Kos I; Prkačin I
    Acta Med Croatica; 2014 Dec; 68(4-5):375-81. PubMed ID: 26285470
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
    Brenner BM; Cooper ME; de Zeeuw D; Keane WF; Mitch WE; Parving HH; Remuzzi G; Snapinn SM; Zhang Z; Shahinfar S;
    N Engl J Med; 2001 Sep; 345(12):861-9. PubMed ID: 11565518
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An economic evaluation of the Irbesartan in Diabetic Nephropathy Trial (IDNT) in a UK setting.
    Palmer AJ; Annemans L; Roze S; Lamotte M; Rodby RA; Bilous RW
    J Hum Hypertens; 2004 Oct; 18(10):733-8. PubMed ID: 15116142
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Care of the diabetic patient with end-stage renal disease.
    Markell MS; Friedman EA
    Semin Nephrol; 1990 May; 10(3):274-86. PubMed ID: 2190284
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy.
    Mohanram A; Zhang Z; Shahinfar S; Keane WF; Brenner BM; Toto RD
    Kidney Int; 2004 Sep; 66(3):1131-8. PubMed ID: 15327408
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diabetes-related end-stage renal disease in Austria 1965-2013.
    Prischl FC; Auinger M; Säemann M; Mayer G; Rosenkranz AR; Wallner M; Kramar R;
    Nephrol Dial Transplant; 2015 Nov; 30(11):1920-7. PubMed ID: 25977308
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study.
    Bakris GL; Weir MR; Shanifar S; Zhang Z; Douglas J; van Dijk DJ; Brenner BM;
    Arch Intern Med; 2003 Jul; 163(13):1555-65. PubMed ID: 12860578
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Value of adding the renal pathological score to the kidney failure risk equation in advanced diabetic nephropathy.
    Yamanouchi M; Hoshino J; Ubara Y; Takaichi K; Kinowaki K; Fujii T; Ohashi K; Mise K; Toyama T; Hara A; Kitagawa K; Shimizu M; Furuichi K; Wada T
    PLoS One; 2018; 13(1):e0190930. PubMed ID: 29338014
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy: cost-effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian and French settings.
    Palmer AJ; Annemans L; Roze S; Lamotte M; Rodby RA; Cordonnier DJ
    Nephrol Dial Transplant; 2003 Oct; 18(10):2059-66. PubMed ID: 13679481
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.